Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aquestive Therapeutics Inc AQST

Healthcare
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on... see more

Recent & Breaking News (NDAQ:AQST)

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

GlobeNewswire 12 days ago

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire November 4, 2024

Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm(TM) (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College of Allergy Asthma and Immunology (ACAAI) 2024 Annual Meeting

GlobeNewswire October 25, 2024

Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm(TM) (epinephrine) Sublingual Film

GlobeNewswire October 24, 2024

Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET

GlobeNewswire October 21, 2024

Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day

GlobeNewswire September 27, 2024

Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th

GlobeNewswire September 9, 2024

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

GlobeNewswire August 22, 2024

Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm(TM)

GlobeNewswire August 14, 2024

Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire August 6, 2024

Aquestive Therapeutics Reports Positive Topline Data for Anaphylm(TM) (epinephrine) Sublingual Film from Self-Administration Study

GlobeNewswire July 25, 2024

Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET

GlobeNewswire July 23, 2024

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

GlobeNewswire June 27, 2024

Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm(TM) (epinephrine) Sublingual Film

GlobeNewswire June 25, 2024

Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024

GlobeNewswire June 18, 2024

Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities

GlobeNewswire June 3, 2024

Aquestive Therapeutics to Present Anaphylm(TM) (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference

GlobeNewswire May 28, 2024

Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference

GlobeNewswire May 9, 2024

Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire May 7, 2024

Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant(TM) (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm(TM) (epinephrine) Sublingual Film

GlobeNewswire April 29, 2024